The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 14, 2023

Filed:

Feb. 24, 2022
Applicant:

Nantbio, Inc., Culver City, CA (US);

Inventors:

Clifford Anders Olson, Culver City, CA (US);

Kayvan Niazi, Culver City, CA (US);

Helty Adisetiyo, Culver City, CA (US);

Hermes J. Garban, Culver City, CA (US);

Mark Guido, Culver City, CA (US);

Heather McFarlane, Los Angeles, CA (US);

Tan Trinh, Culver City, CA (US);

Shiho Tanaka, Culver City, CA (US);

Assignee:

NantBio, Inc., Culver City, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 39/3955 (2013.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/7155 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01);
Abstract

Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against CD30. Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals diagnosed with hematopoietic malignancies, including Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, CD30-positive NK cell lymphomas.


Find Patent Forward Citations

Loading…